Rheumatology
From the Journals
Despite global decline, rheumatic heart disease persists in poorest regions
From 1990 to 2015, the percentage of deaths worldwide due to rheumatic heart disease rose in endemic regions of Oceania, South Asia, and central...
From the Journals
Oral contraceptive use linked to lower rheumatoid arthritis risk
The decrease in risk was seen only in women with ACPA-positive RA.
Conference Coverage
How to make the move away from opioids for chronic noncancer pain
How do physicians treat patients with chronic pain and guard against addiction?
Conference Coverage
Helpful schedules ease task of tapering opioids
ESTES PARK, COLO. – Patients generally tolerate gradual weaning to 30%-50% of original dose.
From the Journals
Radiographic progression in axial spondyloarthritis moves slowly in first 5 years
The net percentage of patients who progressed was 5%, calculated as those who went from nonradiographic axSpA to radiographic axSpA minus those...
Conference Coverage
VIDEO: Triple therapy study and new recommendations provide guidance on CAPS
MADRID – New data confirm that triple therapy with anticoagulation, corticosteroids, and plasma exchange or intravenous immunoglobulins increases...
From the Journals
For acute gout, corticosteroids look safer than NSAIDs
A meta-analysis of six randomized, controlled trials suggests equal efficacy, but patients taking corticosteroids had a lower frequency of...
From the Journals
CT scoring system may improve sacroiliitis treatment in IBD
Sacroiliitis is three times more prevalent among IBD patients and can be reliably detected in CT scans.
Conference Coverage
Attitudes and beliefs affecting methotrexate adherence identified
MADRID – About one-third of RA patients were nonadherent to methotrexate at the time they were eligible to start biologic therapy in one survey....
Conference Coverage
Novel knee osteoarthritis drugs target pain, joint space narrowing
MADRID – Two experimental therapies show promise as future alternatives to current therapies.
Latest News
Self-injectable belimumab receives FDA approval for systemic lupus erythematosus
The new formulation is the first self-injectable subcutaneous treatment available for patients with SLE.